Trial
NCT03125200
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
ADC Therapeutics S.A.
Collaborators
—
Condition
Breast Cancer
Intervention
ADCT-502
Why stopped
Safety
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-01